CONSTITUENT REPORT
Isoleptospermone
Isoleptospermone is a manuka-associated beta-triketone best known as one of the characteristic triketones of Leptospermum scoparium oil rather than as a mainstream fragrance ingredient. The live evidence base is modest but usable: public sources support identity, occurrence in manuka oil, early antimicrobial characterization, and a newer scabies-mite screening paper that tested the isolated constituent directly. Those findings remain laboratory-stage evidence, so AromaForge should present isoleptospermone as a manuka chemistry marker with emerging preclinical activity data rather than a validated therapeutic active.
Chemical identity and composition
PubChem identifies isoleptospermone as CID 59518515 with formula C15H22O4, InChIKey ZDZMTTISWJCOAE-UHFFFAOYSA-N, and the IUPAC name 2,2,4,4-tetramethyl-6-(2-methylbutanoyl)cyclohexane-1,3,5-trione. The FDA GSRS/precisionFDA record ties the name to UNII I1GHU5G4KJ and shows both CAS 5009-05-2 and the alternate CAS 7375-66-8. In the local archive's manuka record, isoleptospermone is directly quantified at 4.05%, reinforcing its relevance as a real manuka triketone rather than a literature-only synonym.
Aroma and practical use
- Use the recorded manuka-like, medicinal, warm, herbaceous descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 1999 Journal of Natural Products paper on Myrtaceae beta-triketones reported isoleptospermone from Leptospermum scoparium, described these compounds as the main antimicrobial components in the essential oil, and noted full spectral characterization for isoleptospermone.
A 1999 Journal of Natural Products paper on Myrtaceae beta-triketones reported isoleptospermone from Leptospermum scoparium, described these compounds as the main antimicrobial components in the essential oil, and noted full spectral characterization for isoleptospermone.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2025 Phytomedicine study reported that flavesone, leptospermone, and isoleptospermone effectively killed scabies mites and eggs at early and late developmental stages, with the authors proposing inhibition of tyrosine catabolism as a likely mechanism.
A 2025 Phytomedicine study reported that flavesone, leptospermone, and isoleptospermone effectively killed scabies mites and eggs at early and late developmental stages, with the authors proposing inhibition of tyrosine catabolism as a likely mechanism.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2020 full-text manuka essential-oil study identified alpha-pinene, isoleptospermone, leptospermone, cubenol, and gamma-muurolene among compounds present in the bioactive fraction of Leptospermum scoparium oil.
A 2020 full-text manuka essential-oil study identified alpha-pinene, isoleptospermone, leptospermone, cubenol, and gamma-muurolene among compounds present in the bioactive fraction of Leptospermum scoparium oil.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Within the archive's current manuka record, isoleptospermone was directly quantified at 4.05% in a 2025 GC/MS report.
Within the archive's current manuka record, isoleptospermone was directly quantified at 4.05% in a 2025 GC/MS report.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
The Good Scents isoleptospermone entry reviewed in this pass presents the material as a cosmetic ingredient for skin and hair conditioning and shows placeholder-style 'not for fragrance use' and 'not for flavor use' recommendations rather than a validated finished-product safety limit.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
No constituent-specific human safety trial, IFRA restriction, or dermal maximum for isolated isoleptospermone was verified in the public sources reviewed here.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
The strongest direct activity evidence remains laboratory-stage antimicrobial and mite-screening work, so archive copy should not present isoleptospermone as a proven therapeutic agent.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
These are research candidates recorded in the interaction matrix. They do not add a proven-amplification bonus to the score.
LeptospermoneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Leptospermone report →How the effects were investigated
possible tyrosine catabolism interference in scabies model
A 2025 scabies study concluded that flavesone, leptospermone, and isoleptospermone likely act through inhibition of tyrosine catabolism, nominating mite HPPD as a potential target, but this remains an in vitro plus in silico proposal.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (7)
- No human clinical evidence for isolated isoleptospermone was located.
- Direct safety literature for the isolated constituent is sparse compared with identity and occurrence data.
- The strongest mechanism story currently depends on a 2025 scabies paper and remains provisional rather than broadly established.
- No IFRA Standard, RIFM fragrance safety assessment, or Tisserand & Young dermal-limit entry was located for isoleptospermone (CAS 5009-05-2) in this pass; the prior unsourced 0.1% dermal_limit_pct placeholder has been removed.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Interaction candidates lack an attached source citation and remain unqualified.